What changed: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Every dated change on the records linked to Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Regulatory1Trial result4Milestone8This record1
September 2026 · 1
August 2024 · 1
2024 · 2
2023 · 2
2016 · 3
- 2016Trial resultEORTC 22033-26033EORTC 22033-26033 reported
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
- 2016MilestoneProcarbazineRTOG 9802: radiotherapy plus PCV for high-risk grade 2 glioma, including oligodendroglioma
A milestone in how this cancer is treated.
- 2016MilestoneOligodendroglioma, IDH-mutant and 1p/19q-codeletedWHO 2016 defines oligodendroglioma by IDH mutation and 1p/19q codeletion
A milestone in how this cancer is treated.
2013 · 3
- 2013Trial resultEORTC 26951EORTC 26951 reported
Median overall survival 42.
- 2013Trial resultRTOG 9402RTOG 9402 reported
1p/19q co-deleted: median overall survival 14.
- 2013MilestoneRTOG 9402Long-term results: radiotherapy plus PCV doubles survival in codeleted tumours
RTOG 9402 median 14.7 versus 7.3 years; EORTC 26951 median not reached versus 112 months (both JCO).